| Literature DB >> 33066298 |
Yunshao Xu1, Zheling Feng1, Tian Zhang1, Peng Lv1, Jun Cao1, Dan Li2, Cheng Peng2, Ligen Lin1,2.
Abstract
Protein-tyrosine phosphatase 1B (PTP1B) has been considered as a promising target for treating insulin resistance. In searching for naturally occurring PTB1B antagonists, two new pimarane diterpenoids, named 2α-hydroxy-7-oxo-pimara-8(9),15-diene (1) and 19-hydroxy-2α-acetoxy-7-oxo-pimara-8(9),15-diene (2), were isolated from the seeds of Caesalpinia minax. Their structures were determined by extensive analysis of NMR and HR-ESIMS data, and their absolute configurations were determined by electronic circular dichroism (ECD) spectra. Compound 1 was disclosed as a competitive inhibitor of PTP1B with an IC50 (the half-maximal inhibitory concentration) value of 19.44 ± 2.39 µM and a Ki (inhibition constant) value of 13.69 ± 2.72 μM. Moreover, compound 1 dose-dependently promoted insulin-stimulated glucose uptake in C2C12 myotubes through activating insulin signaling pathway. Compound 1 might be further developed as an insulin sensitizer.Entities:
Keywords: C2C12 myotubes; Caesalpinia minax; PTP1B; glucose uptake; pimarane diterpenoids
Mesh:
Substances:
Year: 2020 PMID: 33066298 PMCID: PMC7587383 DOI: 10.3390/molecules25204674
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
1H- and 13C-NMR Spectroscopic Data (CDCl3) for Compounds 1 and 2 (δH in ppm, J in Hz).
| Position | 1 | 2 | ||
|---|---|---|---|---|
|
|
| |||
| 1 | α 2.21, m | 45.0 | α 2.21, m | 40.8 |
| 2 | 3.99, tt (11.5, 4.1) | 65.1 | 5.16, tt (11.7, 4.3) | 68.4 |
| 3 | α 1.85, ddd (12.5, 4.1, 2.2) | 50.5 | α 1.69, m | 40.0 |
| 4 | ‒ | 34.8 | ‒ | 39.0 |
| 5 | 1.71, m | 49.4 | 2.13, m | 42.3 |
| 6 | α 2.53, m | 35.3 | α 2.45, dd (17.6, 4.0) | 34.9 |
| 7 | ‒ | 199.7 | ‒ | 199.1 |
| 8 | ‒ | 129.1 | ‒ | 129.3 |
| 9 | ‒ | 164.6 | ‒ | 164.3 |
| 10 | ‒ | 41.2 | ‒ | 40.8 |
| 11 | α 2.31, m | 22.9 | α 2.25, m | 22.9 |
| 12 | 1.44‒1.52, m (2H) | 33.1 | 1.45‒1.49, m (2H) | 33.5 |
| 13 | ‒ | 33.6 | ‒ | 34.3 |
| 14 | α 2.34, m | 33.6 | α 2.32, m | 33.0 |
| 15 | 5.74, dd (17.4, 10.8) | 147.2 | 5.73, dd (17.4, 10.8) | 147.1 |
| 16 | 4.90, m (2H) | 111.0 | 4.90, m (2H) | 111.0 |
| 17 | 0.95, s | 24.9 | 0.95, s | 24.9 |
| 18 | 0.96, s | 32.6 | 3.43, 3.15, d (10.9) | 70.1 |
| 19 | 0.97, s | 22.4 | 0.94, s | 18.2 |
| 20 | 1.10, s | 19.5 | 1.18, s | 19.8 |
| 2- | ‒ | ‒ | ‒ | 170.7 |
| 2- | ‒ | ‒ | 2.05, s | 21.6 |
Data measured at 600 MHz. Data measured at 150 MHz.
Figure 1Chemical structures of compounds 1 and 2.
Figure 2Protein-tyrosine phosphatase 1B (PTP1B) inhibitory activity and kinetic analysis for compound 1. Concentration—PTP1B inhibition ratio curves of compound 1 (A) and the positive control oleanolic acid (B). (C) Lineweaver-Burk plot for the inhibition of PTP1B by compound 1. (D) Dixon plot for the inhibition of the PTP1B by compound 1. Data are expressed as mean ± SD, n = 4.
Figure 3Compound 1 enhanced insulin-stimulated glucose uptake on C2C12 myotubes through activating insulin signaling pathway. (A) Cytotoxicity of compound 1 on C2C12 myotubes when treated for 24 h by MTT assay. (B) Compound 1 increased insulin-stimulated glucose uptake on C2C12 myotubes. AICAR was used as a positive control. (C) Compound 1 activated the insulin signaling pathway in C2C12 myotubes. The expressions of p-IRS-1, IRS-1, p-Akt, Akt, and GAPDH were analyzed by Western blots. “+” means presence, and “−” means absence. Data are expressed as mean ± SD, n = 6. # p < 0.0001, control vs. insulin; * p < 0.001, compound 1 or AICAR vs. insulin.